Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Ligachem Biosciences Inc. (141080:KRX), powered by AI.
Ligachem Biosciences Inc. is currently trading at ₩198,000. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Ligachem Biosciences Inc. on Alpha Lenz.
Ligachem Biosciences Inc.'s P/E ratio is 874.1.
“Ligachem Biosciences Inc. trades at a P/E of 874.1 (premium valuation) with modest ROE of 2.0%. 3Y revenue CAGR of 57.6% highlights clear growth momentum.”
Ask for details →Ligachem Biosciences Inc. is a prominent player in the biopharmaceutical industry, primarily engaged in the discovery and development of innovative therapeutic solutions. The company focuses on leveraging cutting-edge research and advanced biotechnology to address unmet medical needs globally. Through its strategic R&D initiatives, Ligachem Biosciences Inc. develops a diverse pipeline of drug candidates aimed at treating a wide range of diseases, including rare genetic disorders, cancer, and infectious diseases. The company operates in collaboration with academic institutions, healthcare providers, and pharmaceutical companies to accelerate the process of bringing new treatments to market. By prioritizing the integration of scientific expertise and technology, Ligachem Biosciences Inc. plays a critical role in advancing healthcare and improving patient outcomes worldwide. Its commitment to innovation and collaboration distinguishes it within the competitive landscape of biotechnology, contributing significantly to the industry's growth and evolution.
“Ligachem Biosciences Inc. trades at a P/E of 874.1 (premium valuation) with modest ROE of 2.0%. 3Y revenue CAGR of 57.6% highlights clear growth momentum.”
Ask for details →Ligachem Biosciences Inc. (ticker: 141080) is a company listed on KRX in the Healthcare sector (Biotechnology). It has approximately 170 employees. Market cap is $7.2T.
The current price is ₩198,000 with a P/E ratio of 874.09x and P/B of 11.07x.
ROE is 2.04% and operating margin is -16.61%. Annual revenue is $125.9B.